Modified of cisplatin dose because of toxicities would compromise survival in head and neck cancer patients receiving chemoradiation therapy.

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-098
• By: KUO, Jen-Hua (E-DA HOSPITAL, Kaohsiung City, China Taiwan)
• Co-author(s): Jen-Hua Kuo: Pharmacy, E-DA Hospital, Kaohsiung City, Taiwan, Province of China;Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
  Yu-Chen Pan: Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
  Yi-Ping Hsiang: Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
  Yu-Chiun Sun: Department of Hematology/Oncology, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
  
• Abstract:

  Background

  Standard cisplatin-based concurrent chemoradiotherapy (CCRT) has significantly improved locoregional control and survival in advanced squamous cell carcinoma of head and neck (SCCHN). However, this regimen has the disadvantages of intolerance and poor Compliance.

  Purpose

  To evaluate the impact of cisplatin dose reduction on prognosis of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login